摘要
目的:观察养阴生肌散对糖尿病大鼠皮肤溃疡组织转化生长因子β1(TGF-β1)、碱性成纤维细胞生长因子(b FGF)和血管内皮生长因子(VEGF)表达的影响。方法:以STZ腹腔注射诱导糖尿病模型,成模27只糖尿病大鼠切除皮肤制备皮肤溃疡模型。随机分为模型组、阳性药组和养阴生肌散组,每组9只,另取10只大鼠作空白对照。分别于给药3、7、14 d记录皮肤愈合面积,计算愈合率;于第14 d采用免疫组织化学法检测皮肤创面组织TGF-β1、b FGF和VEGF的表达。结果:与模型组比较,其他各组大鼠创面愈合率明显提高,在给药第7、14d与模型组比较差异具有统计学意义(P<0.05,P<0.01),养阴生肌散组在第14 d愈合率明显高于美肤宝对照组(P<0.05)。模型组大鼠皮肤溃疡组织TGF-β1、b FGF和VEGF表达明显低于空白对照组(P<0.01),给药组表达量明显高于模型组,养阴生肌散组表达高于阳性对照组(P<0.05)。结论:养阴生肌散通过增强皮肤组织TGF-β1、b FGF和VEGF蛋白的表达促进糖尿病大鼠皮肤溃疡的愈合。
Objective：To observe the effects of Yangyin Shengji Powder on TGF-β1,b FGF and VEGF expressions in skin ulcers of diabetic rats.Methods：Models of diabetes were induced by STZ intraperitoneal injection,rats＇ skin was cut off to copy skin ulcers models.27 diabetic rats with skin ulcers were randomly divided into model,positive control and Yangyin Shengji Powder groups with each 9 rats,10 normal rats were taken as normal control group.Rats＇ healing area were recorded and healing rate was counted on the 3 rd,7 thand 14 th day,TGF-β1,b FGF and VEGF expressions in skin ulcers were determined by immunohistochemistry method.Results：The healing rate of model group was significantly lower than that in the other groups（ P〈0.05,P〈0.01） on the 7 th,and 14 thday,that of Yangyin Shengji Powder group on the 14 thday was significantly high than that of positive group（ P〈0.05）.The TGF-β1,b FGF and VEGF expressions in skin ulcers were obviously lower than those in normal control group（ P〈0.01）,the expressions in medicine groups were significantly higher than those in model group（ P〈0.05）,those in Yangyin Shengji Powder group were higher to compare with positive group（ P〈0.05）.Conclusion：Yangyin Shengji Powder can promote skin ulcers healing by strengthening TGF-β1,b FGF and VEGF protein expressions.
作者
刘建东
刘海鹰
LIU Jiandong;LIU Haiying(People＇ s Hospital of Ganzhou District,Zhangye,Gansu 734000;Affiliated Medical School of Hexi College,Zhangye,G ansu 734000)
出处
《中国中医药科技》
CAS
2018年第4期485-487,490,共4页
Chinese Journal of Traditional Medical Science and Technology
基金
甘肃省中医药管理局科研课题(GSK-2015-09)
